首页> 外文期刊>Journal of computer assisted tomography >Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma.
【24h】

Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma.

机译:Ferucarbotran增强的3.0-T磁共振成像使用并行成像技术与三相多探测器行计算机断层摄影术进行比较,用于术前检测肝细胞癌。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To compare diagnostic performance of ferucarbotran-enhanced 3.0-T magnetic resonance (MR) imaging using parallel imaging technique with that of triple-phase multidetector row computed tomography (MDCT) for the preoperative detection of hepatocellular carcinoma (HCC). METHODS: Eighty-six consecutive patients with a total of 128 surgically proven HCCs were enrolled in this study. All patients underwent ferucarbotran-enhanced 3.0-T MR imaging using parallel imaging technique and triple-phase MDCT before hepatic resection. Three experienced radiologists independently analyzed each images on a segment-by-segment basis. The accuracy of these techniques for the detection of HCC was assessed by performing a receiver operating characteristic (ROC) analysis of 104 resected hepatic segments with at least 1 HCC and 113 resected hepatic segments without HCC. RESULTS: The mean value of the area under the ROC curve (Az) of the ferucarbotran-enhanced 3.0-T MR imaging (0.990) was significantly higher than that of the triple-phase MDCT (0.964) (P = 0.00). The mean sensitivity of the ferucarbotran-enhanced 3.0-T MR imaging (98.1%) was significantly higher than that of the triple-phase MDCT (92.9%) (P = 0.00). The higher sensitivity was largely attributable to a greater ability of the 3.0-T MR imaging to detect small HCC (< or =1 cm) (92.6% in 3.0-T MR imaging and 37.0% in MDCT; P = 0.00). No significant difference was found for their mean specificities (98.2% in 3.0-T MR imaging and 97.6% in MDCT; P = 0.86). CONCLUSIONS: Ferucarbotran-enhanced 3.0-T MR imaging using parallel imaging technique is a more accurate diagnostic tool than triple-phase MDCT for the preoperative detection of HCC. Ferucarbotran-enhanced 3.0-T MR imaging has a higher sensitivity than triple-phase MDCT, especially for small HCCs (< or =1 cm).
机译:目的:比较使用并行成像技术与三相多探测器行计算机断层扫描(MDCT)对阿魏卡伯特增强的3.0-T磁共振(MR)成像在术前检测肝细胞癌(HCC)的诊断性能。方法:该研究纳入了86例连续的患者,总共128例经手术证实的HCC。所有患者均在肝切除前接受了平行成像技术和三相MDCT对阿魏卡伯特增强的3.0-T MR成像。三位经验丰富的放射科医生逐段地独立分析每个图像。通过对至少有1个HCC的104个切除的肝段和没有HCC的113个切除的肝段进行接收器操作特征(ROC)分析,评估了这些检测HCC技术的准确性。结果:阿卡波朗增强的3.0-T MR成像的ROC曲线下面积(Az)的平均值(0.990)明显高于三相MDCT的平均值(0.964)(P = 0.00)。 Ferucarbotran增强的3.0-T MR成像的平均灵敏度(98.1%)显着高于三相MDCT的平均灵敏度(92.9%)(P = 0.00)。较高的灵敏度主要归因于3.0-T MR成像检测较小HCC(<或= 1 cm)的能力(3.0-T MR成像为92.6%,MDCT为37.0%; P = 0.00)。两者的平均特异性无显着差异(3.0-T MR成像中为98.2%,MDCT为97.6%; P = 0.86)。结论:使用Ferrucarbotran增强的3.0-T MR成像使用并行成像技术,比三相MDCT对HCC的术前检测更为准确。 Ferucarbotran增强的3.0-T MR成像比三相MDCT具有更高的灵敏度,尤其是对于小型HCC(<或= 1 cm)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号